Biblio
Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am J Transplant. 2024.
Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther. 2023.
A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exerc Immunol Rev. 2015;21:144-153.
. Scheduled Administration of Virus-Specific T cells for Viral Prophylaxis After Pediatric Allogeneic Stem Cell Transplant. Blood Adv. 2022.
High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2021.
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023.
Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014(1):565-569.
. Controlling cytomegalovirus: helping the immune system take the lead. Viruses. 2014;6(6):2242-58.
. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation. Pediatr Blood Cancer. 2023:e30577.
. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun. 2024;15(1):3258.
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013;8(10):e76781.
Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood. Cytotherapy. 2015.
. Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024.
.